$3.240
+0.072 (+2.21%)At close
Price Predictions
Open in app to unlock longer-horizon forecasts.
XFOR Prediction & Forecast by Similar Chart Analysis
Alphio's XFOR stock price prediction model matches the current X4 Pharmaceuticals Inc tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $3.27 (+0.96%). The 1-week path is $3.21 (-0.87%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.
Should I Buy X4 Pharmaceuticals Inc Stock?
X4 Pharmaceuticals Inc is a good buy right now due to its recent positive earnings report showing a revenue increase of 347.2% year-over-year, with a current price of $3.35 significantly below the analyst target of $12. Additionally, the RSI is at 78.67, indicating strong momentum. The main risk is the upcoming earnings report, with an estimated EPS of -0.19, which could impact investor sentiment.
XFOR stock price ended at $3.24 on Wednesday, after rising +2.21%
X4 Pharmaceuticals Inc (XFOR) last closed at $3.24, gaining +2.21%. These facts feed the 1-day and 1-week XFOR price prediction above.
Forecast Drivers
X4 Pharmaceuticals Inc (XFOR) forecast drivers combine similar chart patterns, seasonality, and moving averages.
Similar patterns
Bullish
Seasonality
Bearish
SMA 20
Bullish
SMA 200
Bearish
Similar Chart Patterns
Stocks whose recent price path most closely matches XFOR, ranked by similarity.
Seasonality analysis for XFOR
Historically the probability of a positive November return for XFOR is 0.00%. April offers the highest probability of a positive month at 65.62%, while October is the weakest seasonal window. Alphio blends this calendar with technical signals and similar chart pattern matching before it writes the forecast.
Related articles
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
- AppLovin Q3 2026 Deep Dive: Beaten-Down S&P Dog Meets Axon Next-Gen Beat-and-Raise—and a $3.2B BuybaAppLovin Q3 2026: $2.185B rev (+55%), EPS $4.30 vs ~$4.03–4.04 Street, Adj EBITDA $1.842B (84%). Beat own guide $100M; Q4 $2.365–2.395B; auth +$3.2B; AH +22–24%.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.